Barclays Raises Hims & Hers (HIMS) Price Target to $39 From $29 on Novo Partnership Momentum and Peptide-Catalyst Opportunity
Barclays raised its price target on Hims & Hers Health (NYSE: HIMS) to $39 from $29 on June 17, citing improved customer-momentum signals from alternative data since the March 9 Novo Nordisk collaboration announcement and the upcoming peptide-catalyst opportunity tied to the July 23-24 PCAC meeting. The firm maintained an Overweight rating; the $39 target implies roughly 21% upside from the prior close. HIMS gained about 6% on the day. Leerink reiterated Market Perform with a $25 PT ahead of the same PCAC meeting, framing potential PCAC approval as an upside catalyst for Hims' growth outlook beyond 2027. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capacity ahead of the regulatory window.